Table 6 Cardiovascular risk factors, markers of diabetes severity, therapeutics and duration of follow-up for patients with (CVEV = 1) and without (CVEV = 0) cardiovascular events
Univariate analysis | CVEV = 1 | CVEV = 0 | p |
|---|---|---|---|
Hypertension, CT (%) | 100 | 92 | ns |
Hypercholesterolemia, CT (%) | 80 | 70.3 | ns |
Increased waist circunference, CT (%) | 87.5 | 84.1 | ns |
Metabolic syndrome, CT (%) | 70 | 69.3 | ns |
Duration of diabetes, CT (years, mean ± sd) | 16 ± 8 | 13 ± 9 | ns |
Diabetic neuropathy, CT (%) | 44.4 | 21.4 | ns |
Diabetic retinopathy/nephropathy, CT (%) | 33.3 | 38.6 | ns |
Hemoglobin A1c, CT (%, mean ± sd) | 7.6 ± 1.3 | 8.3 ± 1.8 | ns |
Microalbuminuria, CT (mg/24h, mean ± sd) | 171.9 ± 291.4 | 45.1 ± 122.6 | ns |
Serum C-reactive protein, CT (mg/dL, mean ± sd) | 0.4 ± 0.2 | 0.4 ± 0.4 | ns |
Percutaneous revascularization, CT (%) | 20 | 5.3 | ns |
Antiplatelets, CT (%) | 70 | 46.7 | ns |
Statins, CT (%) | 80 | 66.7 | ns |
ACE inhibitor/ARB, CT (%) | 100 | 84 | ns |
Oral hypoglycaemic therapy, CT (%) | 80 | 88 | ns |
Insulin therapy, CT (%) | 60 | 49.3 | ns |
Hemoglobin A1c, Fup (%, mean ± sd) | 7.7 ± 1.5 | 7.6 ± 1.6 | ns |
Microalbuminuria, Fup (mg/24h, mean ± sd) | 39.3 ± 46.8 | 39.9 ± 118.4 | ns |
Serum C-reactive protein, Fup (mg/24h, mean ± sd) | 0.7 ± 0.4 | 0.5 ± 0.4 | ns |
Antiplatelets, Fup (%) | 66.7 | 45.8 | ns |
Statins, Fup (%) | 55.6 | 56.2 | ns |
ACE inhibitor/ARB, Fup (%) | 77.8 | 79.2 | ns |
Oral hypoglycaemic therapy, Fup (%) | 83.9 | 86.3 | ns |
Insulin therapy, Fup (%) | 66.7 | 53.4 | ns |
Duration of follow-up (months, mean ± sd) | 45.7 ± 15.6 | 45.2 ± 13.0 | ns |